Diclofenac methyl ester

CAS No. 15307-78-5

Diclofenac methyl ester( —— )

Catalog No. M28130 CAS No. 15307-78-5

Diclofenac methyl ester is a hydrophobic prodrug form of diclofenac which is a non-steroidal anti-inflammatory drug (NSAID).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 45 In Stock
10MG 63 In Stock
25MG 103 In Stock
50MG 150 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Diclofenac methyl ester
  • Note
    Research use only, not for human use.
  • Brief Description
    Diclofenac methyl ester is a hydrophobic prodrug form of diclofenac which is a non-steroidal anti-inflammatory drug (NSAID).
  • Description
    Diclofenac methyl ester is a hydrophobic prodrug form of diclofenac which is a non-steroidal anti-inflammatory drug (NSAID). Diclofenac methyl ester is more soluble than diclofenac acid in isopropylmyristate but with higher toxicity.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    luciferase
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    15307-78-5
  • Formula Weight
    310.17
  • Molecular Formula
    C15H13Cl2NO2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Haneen Amawi, et al. The use of zebrafish model in prostate cancer therapeutic development and discovery. Cancer Chemother Pharmacol. 2021 Mar;87(3):311-325.
molnova catalog
related products
  • Methyl tricosanoate

    Methyl Tricosanoate is a long-chain fatty acid compound present in various antimicrobial and antibacterial agents.

  • Nurr1 agonist 8

    Nurr1 agonist 8 is a low-affinity Nurr1 agonist that can be used to study neurological diseases such as Parkinson's.

  • Hannokinol

    (+)-Hannokinol and MESO-hannokinol can significantly inhibit lipopolysaccharide-induced nitric oxide production in BV2 microglial cells at concentrations ranging from 1 microM to 100 microM.